StreetInsider.com News Articles

Form 8-K Theriva Biologics, Inc. For: Jul 07

Tue, 07 Jul 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260707/26738989.html

Form 8-K Theriva Biologics, Inc. For: Jul 07

Tue, 07 Jul 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260707/26738989.html

Theriva Biologics cleared to begin VIRAGE2 pancreatic cancer trial

Tue, 07 Jul 2026 08:01:08 -0400

Theriva Biologics (NYSE American: TOVX) announced that Spain's Agency of Medicines and Medical Devices (AEMPS) has authorized the company to initiate the VIRAGE2 Phase 2a clinical trial, evaluating more frequent dosing of VCN-01 (zabilugene almadenorepvec) in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).

The trial is a single-arm, open-label study enrolling six evaluable patients at a single site in Spain. Patients are intended to receive at least three doses of VCN-01 administered two months apart, in combination with gemcitabine/nab-paclitaxel standard-of-care chemotherapy. Primary endpoints include the adverse event profile and levels of VCN-01 viral genomes in blood. Secondary endpoints include

Theriva Biologics cleared to begin VIRAGE2 pancreatic cancer trial

Tue, 07 Jul 2026 08:01:08 -0400

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients

Tue, 07 Jul 2026 08:00:00 -0400

- VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial -

- Study builds on positive clinical data from the recent VIRAGE study and feedback from the EMA and FDA recognizing the potential of repeated VCN-01 dosing to provide clinical benefit -

ROCKVILLE, Md., July 07, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Spanish Agency of Medicines and

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients

Tue, 07 Jul 2026 08:00:00 -0400

- VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial -

- Study builds on positive clinical data from the recent VIRAGE study and feedback from the EMA and FDA recognizing the potential of repeated VCN-01 dosing to provide clinical benefit -

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients

Tue, 07 Jul 2026 08:00:00 -0400

- VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial -

- Study builds on positive clinical data from the recent VIRAGE study and feedback from the EMA and FDA recognizing the potential of repeated VCN-01 dosing to provide clinical benefit -

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients

Tue, 07 Jul 2026 08:00:00 -0400

- VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial -

- Study builds on positive clinical data from the recent VIRAGE study and feedback from the EMA and FDA recognizing the potential of repeated VCN-01 dosing to provide clinical benefit -

Form DEF 14A Theriva Biologics, Inc. For: Aug 03

Mon, 29 Jun 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260629/26707751.html

Form DEF 14A Theriva Biologics, Inc. For: Aug 03

Mon, 29 Jun 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260629/26707751.html

Form ARS Theriva Biologics, Inc. For: Dec 31

Mon, 29 Jun 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260629/26707720.html

Form ARS Theriva Biologics, Inc. For: Dec 31

Mon, 29 Jun 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260629/26707720.html

Form PRE 14A Theriva Biologics, Inc. For: Jun 18

Thu, 18 Jun 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260618/26667475.html

Form PRE 14A Theriva Biologics, Inc. For: Jun 18

Thu, 18 Jun 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260618/26667475.html

Form 8-K Theriva Biologics, Inc. For: Jun 11

Thu, 11 Jun 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260611/26632965.html

Form 8-K Theriva Biologics, Inc. For: Jun 11

Thu, 11 Jun 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260611/26632965.html

Theriva Biologics publishes VCN-01 head and neck cancer trial results

Thu, 11 Jun 2026 08:01:56 -0400

Theriva Biologics Inc. (NYSE American: TOVX) announced that results from a Phase 1 clinical trial of its VCN-01 treatment in head and neck cancer patients have been published in Clinical Cancer Research.

The trial enrolled 20 patients with metastatic head and neck squamous cell carcinoma who had previously received anti-PD-(L)1 immune checkpoint inhibitors. Patients were divided into three treatment groups receiving different doses and timing of VCN-01 administered before the immune checkpoint inhibitor durvalumab.

The study reported median overall survival of 10.3 months for patients receiving low-dose VCN-01 four hours before durvalumab, 15.5 months for those receiving low-dose VCN-01 fourteen days before

Theriva Biologics publishes VCN-01 head and neck cancer trial results

Thu, 11 Jun 2026 08:01:56 -0400

The study reported median overall survival of 10.3 months for patients receiving low-dose VCN-01 four hours before durvalumab, 15.5 months for those receiving low-dose VCN-01 fourteen days before

Theriva Biologics publishes VCN-01 head and neck cancer trial results

Thu, 11 Jun 2026 08:01:56 -0400

The study reported median overall survival of 10.3 months for patients receiving low-dose VCN-01 four hours before durvalumab, 15.5 months for those receiving low-dose VCN-01 fourteen days before

Theriva Biologics publishes VCN-01 head and neck cancer trial results

Thu, 11 Jun 2026 08:01:56 -0400

The study reported median overall survival of 10.3 months for patients receiving low-dose VCN-01 four hours before durvalumab, 15.5 months for those receiving low-dose VCN-01 fourteen days before

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

Thu, 11 Jun 2026 08:00:00 -0400

– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab –

– Pharmacokinetic, tissue biopsy, radiomic and transcriptomic results all support the proposed VCN-01 stroma-degrading and immune enhancing modes-of-action and resensitization of refractory tumors to durvalumab -

– Increased levels of PD-L1 positive T-cells and other biomarkers were found in patients after sequential administration of VCN-01 and durvalumab, consistent with reactivation of immune responses –